Andrea Mckenzie

Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada (Fancy, Rodrigues, Di Vicenzo, Sethi, Gill, Tabassum, Mckenzie, Phan, McIntyre, Rosenblat); Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada (Fancy, Gill, McIntyre, Rosenblat); Braxia Scientific, Braxia Health, Canadian Rapid Treatment Centre of Excellence, Mississauga, Ontario, Canada (Chau, McIntyre, Rosenblat); Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada (Sethi, Husain, McIntyre, Rosenblat); Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada (Husain); Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada (McIntyre, Rosenblat); Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada (McIntyre).

2 papers in the library · 50 citations · publishing 2023

Papers

The Role of Ketamine in the Treatment of Bipolar Depression: A Scoping Review.

Brain sciences June 4, 2023 Muhammad Youshay Jawad, Saleha Qasim, Menglu Ni et al. 46 citations

Ketamine shows promise as a treatment for bipolar depression, though evidence remains weak. A scoping review of 10 clinical studies (5 randomized controlled trials and 5 open-label studies) found that ketamine was generally tolerable, with minimal risk of triggering manic or hypomanic episodes, and demonstrated some effectiveness in reducing depressive symptoms and suicidality. The treatment may be particularly useful for patients with treatment-resistant bipolar depression. However, more research is needed to establish ketamine's role in both acute and maintenance treatment phases, and to study its potential for preventing recurrence and suicidal behavior.

DOI: 10.3390/brainsci13060909 Full text Ketamine Bipolar depression Bipolar disorder Mood disorders +1

Real-World Effectiveness of Repeated Ketamine Infusions for Treatment-Resistant Bipolar Depression.

Focus (American Psychiatric Publishing) October 1, 2023 Farhan Fancy, Nelson B Rodrigues, Joshua D Di Vincenzo et al. 4 citations

Repeated intravenous ketamine infusions significantly reduced depression, suicidal thoughts, and anxiety in patients with treatment-resistant bipolar I/II depression, and improved functioning. In an observational study of 66 patients receiving four infusions over two weeks, depressive symptoms dropped by an average of 6.08 points on the QIDS-SR16 scale. Response rate was 35% and remission rate 20%. Hypomania occurred in only 4.5% of patients, with no mania or psychosis. The findings suggest real-world effectiveness and tolerability of IV ketamine for bipolar depression.

DOI: 10.1176/appi.focus.23021022 Full text Esketamine Major depressive disorder Treatment-resistant depression Bipolar disorder +9